Akari Therapeutics Announces Positive Results from Recent Pre-Clinical Studies of Investigational PASylated^® Nomacopan That Support the Potential to Advance Research Toward IND/IMPD for Clinical Trials in Geographic Atrophy

Akari Therapeutics, Plc announced positive results from recent pre-clinical studies on the tolerability and extended dose interval of long-acting PAS-nomacopan in development for geographic atrophy in dry age-related macular degeneration.